Homo sapiens
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA192516 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Enzalutamide (formerly MDV3100 and available commercially as Xtandi), a novel androgen receptor (AR) signaling inhibitor, blocks the growth of castration-resistant prostate cancer (CRPC) in cellular model systems and was shown in a clinical study to increase survival in patients with metastatic CRPC. Enzalutamide inhibits multiple steps of AR signaling: (1) binding of androgens to AR, (2) AR nuclear translocation, and (3) association of AR with DNA. Here we used Affymetrix human genome microarray technology to investigate the global programme of gene expression of LNCaP cells in response to enzalutamide alone and in the context of DHT-stimulated androgen receptor gene expression. LNCaP cells were grown in RPMI 1640 supplemented with 5% hormone depleted FBS and treated with vehicle (control sample) , DHT (100 nM), enzalutamide (1 or 10 M-BM-5M) or DHT (100 nM) plus enzalutamide (1 or 10 M-BM-5M)for 16 hours for RNA extraction and hybridization. Each condition was done in triplicate.
2013-04-01 | E-GEOD-44905 | biostudies-arrayexpress
Project description:Gene expression in rat ovaries treated with DHT
2016-04-07 | E-GEOD-59456 | ExpressionAtlas
Project description:Expression data for T47D cells treated with 2mM hydroxyurea
2025-01-24 | E-GEOD-56940 | ExpressionAtlas
Project description:Expression data from untreated and Aza treated AML3 cells
2025-01-24 | E-GEOD-55123 | ExpressionAtlas
Project description:Expression data from AsPC1 cells treated with ICG-001
2025-01-24 | E-GEOD-57728 | ExpressionAtlas
Project description:The goal of this study was to determine how androgen receptor inhibition alters transcriptional programs in prostate cancer cells. LNCaP prostate cancer cells were grown in 10% charcoal-stripped serum (CSS) supplemented with 0.5 nanomolar dihydrotestosterone (DHT), in CSS without DHT modeling castration, with CSS + DHT but in the presence of 10 micromolar enzalutamide, or in CSS without DHT (castrated) and in the presence of enzalutamide for 72 hours. Analysis shows that androgen receptor target genes are reduced with castration, enzalutamide or the combination of castration + enzalutamide.
2022-05-12 | GSE202755 | GEO
Project description:Expression Data from DMSO or SRPIN803 treated ARPE-19 cells
2025-01-24 | E-GEOD-62947 | ExpressionAtlas
Project description:Expression data from DHT stimulation vs. control in LNCaP cells
| PRJNA114289 | ENA
Project description:Expression data from TGFbeta-treated control or aPKC silenced A549 cells
2025-01-24 | E-GEOD-26241 | ExpressionAtlas
Project description:Expression data from glucocorticoid-treated ALL (CCRF-CEM-C7-14 cells)
2025-01-24 | E-GEOD-39338 | ExpressionAtlas